EQS-Adhoc : IGEA to finalize on convertible bond facility arrangement

EQS Group-Ad-hoc: IGEA Pharma N.V. / Key word(s): Miscellaneous 
IGEA to finalize on convertible bond facility arrangement 
25-March-2021 / 20:56 CET/CEST 
Release of an ad hoc announcement pursuant to Art. 18 KR 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
IGEA to finalize on convertible bond facility arrangement 
Hoofddorp, the Netherlands, 25 March 2021. IGEA Pharma N.V. (SIX: IGPH) today announced the entry into the final stage 
of negotiations with an institutional investor, following to a letter of intent (LOI) binding in terms, for a 
convertible bond facility arrangement over the next 24 months. The closing is expected to be within the first half of 
April 2021. 
Under the terms of the LOI and subject to closing, the investor will commit for up to EUR 10 million over the next 24 
months. 
The funds are intended to be used to further finance the activities of the combined businesses (with Blue Sky Natural 
Resources LTD), which mainly includes the final set-up and launch of all production activities on cannabidiol (CBD), 
terpenes, policosanol, and other extracts from vegetable matrices in the Swiss industrial site within the second half 
of 2021 as well as the ongoing efforts to establish and strengthen both acceptance and market position for health 
prevention, pharma, nutraceutical and cosmeceutical solutions. 
The Company furthermore intends to continue diversifying and optimizing its current finance structure with the aim of 
reducing risks and costs. Discussions are ongoing with further institutional investors potentially interested to 
support the Company in this strategy. 
*** 
About IGEA 
IGEA Pharma N.V. focuses on health-tech and med-tech products and devices. Health-tech products are exclusively 
preventative. IGEA commercializes an Alzheimer's prevention set (which includes 'Alz1', an at-home lab test kit to 
measure non-bound copper in the blood and a natural dietary supplement branded 'Alz1 Tab' designed to reduce blood 
heavy metals content) and expects to integrate the non-bound copper detection-based pipeline with a diabetes type II 
prevention set in 2021. Non-bound copper is an expected Alzheimer's and diabetes type II associated biomarker. 
Controlling non-bound copper can contribute to reduce the risk of Alzheimer's and diabetes type II. IGEA furthermore 
commercializes a COVID19 rapid test for the detection of IgM and IgG SARS-CoV-2 related antibodies. Med-tech products 
focuses on selected solutions and specialties, among which dry aerosol generators for air and inanimate environmental 
surfaces sanitization and sterilization and air purification devices. 
IGEA is listed on the SIX Swiss Exchange (ticker IGPH) and is headquartered in Hoofddorp, the Netherlands. Find out 
more at www.igeapharma.nl 
IGEA Contacts 
Vincenzo Moccia, CEO, [phone], [e-mail] 
Patrick Pozzorini, CFO, [phone], [e-mail] 
Disclaimer 
This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of 
it should form the basis of any investment decision in IGEA. The information contained in this press release has been 
carefully prepared. However, IGEA bears and assumes no liability of whatever kind for the correctness and completeness 
of the information provided herein. IGEA does not assume an obligation of whatever kind to update or correct 
information contained in this press release whether as a result of new information, future events or for other reasons. 
This publication may contain specific forward-looking statements and assessments or intentions concerning IGEA and its 
business. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which 
may result in a substantial divergence between the actual results, financial situation, development or performance of 
IGEA and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, 
readers should not rely on forward-looking statements. IGEA assumes no responsibility to update forward looking 
statements or to adapt them to future events or developments, except as may be required by law. 
Additional features: 
File: 20210325 igea nv_press release 
=---------------------------------------------------------------------------------------------------------------------- 
End of ad hoc announcement 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      IGEA Pharma N.V. 
              Siriusdreef 17 
              2123 WT Hoofddorp 
              Netherlands 
Phone:        [phone] 
E-mail:       [e-mail] 
Internet:     www.igeapharma.nl 
ISIN:         NL0012768675 
Listed:       Regulated Unofficial Market in Frankfurt; BX Berne eXchange; SIX Swiss Exchange 
EQS News ID:  1178715 
 
End of Announcement EQS Group News Service 
=------------ 

1178715 25-March-2021 CET/CEST

(END) Dow Jones Newswires

March 25, 2021 16:00 ET (20:00 GMT)